Abstract:
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.
Abstract:
Therapeutic methods of using certain heterocyclic arylidene aryl ether compounds for treating diseases or disorders mediated through modulation of estrogen related receptor alpha are described.
Abstract:
A system and method are provided for transporting FTFL messages in a G.709 network-connected simplex device. The method comprises: receiving messages from a first source in a digital wrapper frame format with overhead bytes in every frame; recovering FTFL information from the received message overhead bytes; and, selectively supplying modified FTFL information for transmit message overhead bytes to the first source. Recovering FTFL information from the received message overhead bytes includes recovering a 256 byte FTFL message, including a 128-byte forward message and a 128-byte backward message. Selectively supplying modified FTFL information for transmit message overhead bytes to the first source includes the substeps of: examining the received messages to determine errors; generating a backward message to report the determined errors; overwriting the received backward message with the generated backward message to create the modified FTFL information; and, in response to overwriting the received backward message with the generated backward message, sending a FTFL_status_out signal. Then, the method further comprises: transmitting messages to the first source with the modified FTFL information in response to the FTFL_status_out signal.